Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
12.52
-0.06 (-0.48%)
Oct 22, 2024, 4:00 PM EDT - Market closed
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $4.83M in the quarter ending June 30, 2024, a decrease of -294.72%. This brings the company's revenue in the last twelve months to $15.16M, up 71.38% year-over-year. In the year 2023, Stoke Therapeutics had annual revenue of $8.78M, down -29.22%.
Revenue (ttm)
$15.16M
Revenue Growth
+71.38%
P/S Ratio
39.61
Revenue / Employee
$137,791
Employees
110
Market Cap
659.15M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Ironwood Pharmaceuticals | 400.57M |
OrthoPediatrics | 175.07M |
Avid Bioservices | 142.36M |
Y-mAbs Therapeutics | 86.55M |
Exscientia | 26.57M |
ABIVAX Société Anonyme | 9.68M |
Oculis Holding AG | 969.29K |
STOK News
- 6 weeks ago - Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome - Business Wire
- 6 weeks ago - Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome - Seeking Alpha
- 6 weeks ago - Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer - Business Wire
- 7 weeks ago - Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire
- 7 weeks ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in September - Business Wire
- 2 months ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 2 months ago - Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates - Business Wire
- 4 months ago - Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday - Benzinga